bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-31-4023

Order Name (ชื่อการทดสอบ):
RNA Polymerase III Antibodies, IgG, Serum **

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 2 tubes
 
Turnaround Time (ระยะเวลารอผล):
Receive specimen to report within 14 days
 
Useful For (ประโยชน์การทดสอบ):
Evaluating patients suspected of having systemic sclerosis, when used in conjunction with centromere and Scl70 antibodies

Providing diagnostic and prognostic information in patients with systemic sclerosis
 
Methodology (วิธีการทดสอบ):
Enzyme-Linked Immunosorbent Assay (ELISA)
 
AliasesName (ชื่อเรียกอื่นๆ) :
RNA Polymerase 3 Ab, IgG, S
 
 
 
Test Code (รหัสการทดสอบ):
090-31-4023

Order Name (ชื่อการทดสอบ):
RNA Polymerase III Antibodies, IgG, Serum **

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 2 tubes
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 2 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic tube
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Hemolysis: Gross reject
Lipemia: Gross reject
Icterus: OK
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC (preferred) 21 days
Frozen 21 days
 
 
 
Test Code (รหัสการทดสอบ):
090-31-4023

Order Name (ชื่อการทดสอบ):
RNA Polymerase III Antibodies, IgG, Serum **

 
Method detail (วิธีการทดสอบ):
Enzyme-Linked Immunosorbent Assay (ELISA)
 
Schedule (ตารางการทดสอบ):
N/A **Sent out to MAYO, USA
 
Turnaround Time (ระยะเวลารอผล):
Receive specimen to report within 14 days
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
MAYO Laboratory
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code (รหัสการทดสอบ):
090-31-4023

Order Name (ชื่อการทดสอบ):
RNA Polymerase III Antibodies, IgG, Serum **

 
 
Clinical Information (ข้อมูลทางคลินิก):
Systemic sclerosis is a multisystem connective tissue (systemic rheumatic) disease characterized by fibroblast dysfunction leading to fibrosis of the skin and internal organs, microvascular injury leading to tissue hypoxia, and an autoimmune response manifested by production of autoantibodies. The severity of the disease is highly variable among individual patients. Limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis have been recognized as distinct subsets, with worse survival for those with the diffuse form. Clinical features of CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasias) can be seen in both limited cutaneous and diffuse cutaneous forms but, overall, are associated with a better prognosis. Several disease-specific and mutually exclusive autoantibodies have been identified that are helpful in both diagnosis and disease classification. Centromere and topoisomerase I (Scl 70) autoantibodies are associated with limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis, respectively.
 
RNA polymerase III is a complex, 16-subunit enzyme directing transcription of small, stable nontranslated RNA genes: tRNA, 5S rRNA, Alu RNA, U6 snRNA, and 7SK snRNA genes. The immunodominant epitope for autoantibodies with anti-RNA polymerase I/III specificity has been identified on the RNA polymerase-specific subunit RPC155.
 
Autoantibodies to RNA polymerase III antigen are found in 11% to 23% of patients with systemic sclerosis. Systemic sclerosis patients who are positive for RNA polymerase III antibodies form a distinct serologic subgroup and usually do not have any of the other antibodies typically found in systemic sclerosis patients such as anticentromere or anti-Scl70. Numerous studies have shown that systemic sclerosis patients with anti-RNA polymerase III have an increased risk of the diffuse cutaneous form of scleroderma, with a high likelihood of skin involvement and hypertensive renal disease.
 
 
Reference Value (ค่าอ้างอิง):
<20.0 U (negative)
20.0-39.9 U (weak positive)
40.0-80.0 U (moderate positive)
>80.0 U (strong positive)
 
Interpretation (การแปลผล):
A positive result supports a possible diagnosis of systemic sclerosis (see Cautions). This autoantibody is strongly associated with diffuse cutaneous scleroderma and with an increased risk of acute renal crisis. 
 
A negative result indicates no detectable IgG antibodies to RNA polymerase III, but does not rule out the possibility of systemic sclerosis (11%-23% sensitivity).
 
CAUTIONS 
 
A positive result indicates the presence of measurable IgG antibodies to RNA polymerase III, but does not unequivocally establish the diagnosis of systemic sclerosis or other autoimmune disease.
 
The level of RNA polymerase III autoantibodies does not indicate the severity of disease in patients with systemic sclerosis.
 
The presence of immune complexes or other immunoglobulin aggregates in the patient specimen may cause an increased level of nonspecific binding and produce false-positive results with this assay.
 
Clinical Reference (เอกสารอ้างอิง):
www.mayomedicallaboratories.com (Retrieved: 22 Feb 2022)